파라택시스코리아

288330KOSDAQ

54.5 / 100

Reference Date: 2026-10-23

Financial Score22.0 / 40

News Sentiment12.5 / 25

Momentum10.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Roughly flat over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Parataxis Korea operates two main business segments: digital assets and biotechnology. In the digital asset division, the company holds Bitcoin as a strategic financial asset and aims to generate revenue through mining operations. The biotechnology division focuses on developing innovative drugs for unmet medical needs, with key candidates like BBT-207 and BBT-877 currently in clinical trials for lung cancer and idiopathic pulmonary fibrosis, respectively.

Number of Employees

16people

Average Salary

74.5M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

1.01Industry Average 1.204.0Point

In line with industry avg

ROE

-90.37Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

8.93Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20256.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲107.7% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲36.6% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -97.2% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 416Won52-week high 1,55552-week low 416

1-month return3.0Point

1m 0% (flat)

Volume trend6.0Point

Volume surge

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0

Neutral[기재정정]주요사항보고서(회사합병결정)2026-10-06
Neutral[기재정정]주주명부폐쇄기간또는기준일설정 (임시주주총회-철회)2026-10-06
Neutral[기재정정]주주총회소집결의 (임시주주총회-철회)2026-10-06
Neutral기타주요경영사항 (회사합병 결정 및 임시주주총회 소집결의 철회)2026-10-06